FONR Quote, Financials, Valuation and Earnings

OncoCyte has a net margin of 7.87% compared to Fonar's net margin of -2255.11%. Fonar's return on equity of 4.95% beat OncoCyte's return on equity of -581.11%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $4.13 which suggests that it could grow by 39.8%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

Fonar has a beta of 1.274, which suggesting that the stock is 27.394% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.716%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than OncoCyte quarterly revenues of $1.5M. Fonar's net income of $2M is higher than OncoCyte's net income of -$33.5M. Notably, Fonar's price-to-earnings ratio is 11.74x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.85x versus 21.12x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 7.87% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 4.95% beat ProPhase Labs's return on equity of -59.59%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 2775%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

Fonar has a beta of 1.274, which suggesting that the stock is 27.394% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.525, suggesting its less volatile than the S&P 500 by 152.456%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Fonar's net income of $2M is higher than ProPhase Labs's net income of -$6.6M. Notably, Fonar's price-to-earnings ratio is 11.74x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.85x versus 0.70x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 7.87% compared to Fonar's net margin of 4.31%. Fonar's return on equity of 4.95% beat Veracyte's return on equity of 2.14%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $44.50 which suggests that it could grow by 32.09%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Fonar has a beta of 1.274, which suggesting that the stock is 27.394% more volatile than S&P 500. In comparison Veracyte has a beta of 1.800, suggesting its more volatile than the S&P 500 by 80.007%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are smaller than Veracyte quarterly revenues of $118.6M. Fonar's net income of $2M is lower than Veracyte's net income of $5.1M. Notably, Fonar's price-to-earnings ratio is 11.74x while Veracyte's PE ratio is 112.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.85x versus 5.88x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 7.87% compared to Fonar's net margin of -56.4%. Fonar's return on equity of 4.95% beat XWELL's return on equity of -71.82%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 579.61%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

Fonar has a beta of 1.274, which suggesting that the stock is 27.394% more volatile than S&P 500. In comparison XWELL has a beta of 2.555, suggesting its more volatile than the S&P 500 by 155.514%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than XWELL quarterly revenues of $8.4M. Fonar's net income of $2M is higher than XWELL's net income of -$4.8M. Notably, Fonar's price-to-earnings ratio is 11.74x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.85x versus 0.13x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.